Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levisoprenaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 7/20 | 1.00 |
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.80 |
| ▸ | ADRB3 known ✓ | P13945 | 4/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | BLM | P54132 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoproterenol SCHEMBL559248 | 1.00 | KDM4E (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Isoproterenol SCHEMBL31012285 | 1.00 | KDM4E (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Isoproterenol SCHEMBL28173756 | 0.90 | MAPT (0.82) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Levisoprenaline SCHEMBL29620666 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Levisoprenaline SCHEMBL250806 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Isoproterenol SCHEMBL29386243 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Isoproterenol SCHEMBL4166 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Isoproterenol SCHEMBL29519146 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Isoproterenol SCHEMBL3253794 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 | |
| Isoproterenol SCHEMBL4165 | 0.89 | MAPT (1.00) | KDM4EMAPTTDP1ADRB2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220031719-A1 | ANTIVIRAL THERAPEUTIC DRUG COMBINATIONS | THE UNIVERSITY OF TULSA (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031719-A1 | ANTIVIRAL THERAPEUTIC DRUG COMBINATIONS | HK2, G6PD, GCK | ADRB2 2308/4885ADRB1 2327/4885ADRB3 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.